Právní předpis byl sestaven k datu 27.04.2026.
Zobrazené znění právního předpisu je účinné od 28.01.2025.
19
SDĚLENÍ
Ministerstva zahraničních věcí,
kterým xx xxxx a xxxxxxxx sdělení Xxxxxxxxxxxx xxxxxxxxxxxx xxxx č. 58/2007 Sb. m. s. x č. 46/2008 Sb. m. s.
&xxxx;
Xxxxxxxxxxxx zahraničních xxxx xxxxxxx, že xxx 1. xxxxx 2023 bylo xxxxxxxxx xxxxxxxxxx XXXXXX xxxxxxxx xxxxxxxxx nového znění Xxxxxxx X - Xxxxxx xxxxxxxxxx xxxxx x xxxxx xxxxxxx xxx rok 2024 - Xxxxxxxxxxx xxxxxxxx Xxxxxxxxxxx úmluvy xxxxx xxxxxxx xx xxxxxx.
X xxxxx xxxxxx Přílohy X xxxxxxxx xxxxxxx Xxxxxxxxx Xxxxx xxxxxxxxx x xxxxxxxxx republiky xxxxxxxx xxxxxxx o xxxxxxx xxxx Xxxxxxx X Xxxxxx republikou.
Nové xxxxx Přílohy X xxxxxxxxx v xxxxxxxx x xxxxxxx s článkem 34 xxxx. 3 Xxxxxx xxx 1. xxxxx 2024, pro Xxxxxx republiku xxxxxxxxx x xxxxxxxx xxx 18. xxxxxx 2024 x xxxxxxxxx Xxxxxxx X pro xxx 2023, platnou od 1. xxxxx 2023, xxxxx xxxxxxxxx v xxxxxxxx pro Českou xxxxxxxxx xxx 22. xxxxxx 2023 a xxxx xxxxxxxxx pod č. 32/2023 Sb. m. s.
Xxxxxxxx xxxxx Xxxxxxx X pro xxx 2024 a xxxx xxxxxxx xx xxxxxxx xxxxxx xx xxxxxxxxx xxxxxxxx.
&xxxx;
Xxxxxxx:
x x. JUDr. Xxxxxx, Xx.X., XX.X., x. x.
xxxxxx xxxxxxx xxxxx xxxxxx x xxxxxxxxxx
&xxxx;
Xxxxxxx č. 1
Xxxxxxx xxxxxxxxxxx xxxxxxx do xxxxxxx xxxxxx
Xxxx
Xxxxxx xxxxxxxxxx xxxxx x xxxxx xxxxxxx xx povinný Xxxxxxxxxxx xxxxxxxx x xxxxx Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxxxx.
Xxxxxx je xxxxxxxxxx xxxxxxxxxxxx xx xxxxxxxxx xxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxxxx Xxxxxxxx antidopingovou xxxxxxxxx (XXXX). Seznam xx xxxxxx xx 1. xxxxx 2024.
Xxxxxxxxx text Xxxxxxx xxxxxxxxxx látek x xxxxx xxxx xxxxxxxxx XXXX a xxxx xxxxxxxxxx v xxxxxxxxxx x xxxxxxxxxxxxx. X případě xxxxxxxxxxx xxxxxxxxxxxxx mezi xxxxxxxxx x xxxxxxxxxxxx xxxxxx xxxxxxxxx xxxxx x xxxxxxxxxx.
Xxxx xxxx uvedeny xxxxxxx xxxxx používané x xxxxx Xxxxxxx xxxxxxxxxx xxxxx x xxxxx.
Xxxxxxxx Xxx xxxxxxx
Xxxxx XXXX xxx xxxx xxxxx xxxxxxxxxxx jiné xxxxxx, xx období Xxx soutěži v xxxxxx obdobím xxxxxxxxxxx xxxxx před xxxxxxx (xx 23:59 hodin) x den xxxxxxxxxxxxx Xxxxxxx, xxxxx se xx Xxxxxxxxx xxxxxxxxx, xx xx xxxxx Xxxxxxx x xxxxxxx xxxxxx Xxxxxx.
Xxxxxxxx xxxxx
Xx xxxxxxx, xx daná xxxxx xxxx xxxxxx xx zakázána Xxx xxxxxxx x Xxxx xxxxxx, xxx xx xxxxxxxxxx x Xxxxxx.
Xxxxxxxxxx x Xxxxxxxxxxxx
Xxxxx článku 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx Xxxxxx „xxx účely xxxxxxxx článku 10 xxxxx xxxxxxx Xxxxxxxx xxxxx Specifickými látkami, x xxxxxxxx xxxx xxxxxxxxxx x Xxxxxxx xxxxxxxxxx xxxxx x xxxxx dopingu. Xxxxx Xxxxxxxx xxxxxx nebude Xxxxxxxxxxx xxxxxxx, xxxxx xxxx x Xxxxxxx xxxxxxxxx xxxxxxxx xxxx Xxxxxxxxxx xxxxxx.“ Xxxxx xxxxxxxxx x xxxxxx „Xxxxxxxxxx xxxxx x Xxxxxxxxxx xxxxxx uvedené x xxxxxx 4.2.2 xx xxxxxx být xxxxxx xxxxxxxx xxxxxxxxxx xx méně xxxxxxxx xxxx méně xxxxxxxxxx xxx xxxx xxxxxxxxx xxxxx xxxx metody. Xxx xxxxx x xxxxx a metody, xxxxx Xxxxxxxxx xxxxxxxxxxxxx xxxx xxxx xxxxxx x xxxxxx účelu xxx ke xxxxxxxx xxxxxxxxxxx xxxxxx.“
Xxxxxxxx xxxxx
Xxxxx xxxxxx 4.2.3 Kodexu xxxx Návykové xxxxx xxxxxxxxxx xxxx xxxxx, xxxxx xxxx xxxx xxxxxx xxxxxxxx x xxxxxx jejich xxxxxxx xxxxxxxxxx xx xxxxxxxxxxx xxxx xxxxx sportu. Xxxx Návykové xxxxx xxxx xxxxxxxxxx xxxx xxxxx: kokain, xxxxxxxxx (xxxxxx), xxxxxxxxxxxxxxxxxxxxxxxxx (XXXX/„xxxxxx“), xxxxxxxxxxxxxxxxxxx (XXX).
X0 XXXXXXXXXXX XXXXX
XXXXXXXX XXXXX (XXX XXXXXXX X MIMO XXXXXX)
Xxxxxxx zakázané xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.
Xxxxxxxxx xxxxxxxxxxxxxx látka, xx xxxxxx xx nevztahuje xxxxx z xxxxxxxxxxxxx xxxxxx Seznamu x xxxxx xxxx v xxxxxxxx době schválena xxxxxx xxxxxxx xxxxxxxxxxxxx xxxxxxxxxx xxxxxxx xxx xxxxxxx xxxxxxx x xxxx (např. xxxxxx x xxxxxxxxxxxxx xxxx xxxxxxxxx xxxxxx nebo xxxxxxx vývoj xxx xxxxxxx, xxxxxxxxxx xxxxx, xxxxx xxxxxxxxx xxxxx xxx xxxxxxxxxxx xxxxxxx), xx xxxxxxxx xxxxx.
Xxxx xxxxx xxxxxxxx xxxxx xxxxxxx látek, xxxx xxxx XXX-157, 2,4-dinitrofenol (XXX) x xxxxxxxxxx xxxxxxxxx (xxxx. Xxxxxxxxxxx x Xxxxxxxxxx).
X1 ANABOLICKÉ XXXXX
XXXXXXXX STÁLE (XXX XXXXXXX I MIMO XXXXXX)
Xxxxxxx xxxxxxxx xxxxx x xxxx třídě xxxx Xxxxxxxxxxxx xxxxx.
Xxxxxxxxxx xxxxx jsou xxxxxxxx.
X1.1. XXXXXXXXXX ANDROGENNÍ XXXXXXXX (XXX)
Xxx exogenním podání, xxxx xxxx xxxxxx:
|
• |
1-xxxxxxxxxxxxxx (5ɑ-xxxxxxx-1-xx-3ß, 17ß-xxxx) |
&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx;&xxxx; |
&xxxx;•&xxxx; |
xxxxxxxxxx |
|
• |
1-xxxxxxxxxxxxxx (5ɑ-androst-1-en-3,17-dion) |
• |
furazabol (17ɑ-xxxxxx [1,2,5]xxxxxxxxxx[3’,4’:2,3]-5ɑ-xxxxxxxxx-17ß-xx) |
|
|
• |
1-xxxxxxxxxxx (3ɑ-xxxxxxx-5x-xxxxxxx-1-xx-17-xx) |
&xxxx;• |
xxxxxxxxx |
|
|
• |
1-xxxxxxxxxxxxxx (3ß-xxxxxxx-5ɑ-xxxxxxx-1-xx-17-xx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
1-xxxxxxxxxxx (17ß-hydroxy-5ɑ-androst-1-en-3-on) |
• |
mesterolon |
|
|
• |
4-androstenediol (xxxxxxx-4-xx-3ß, 17ß-xxxx) |
&xxxx;• |
xxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxxxxxxxxxxx-1,4-xxxx-3-xx) |
|
|
• |
4-xxxxxxxxxxxxxxxxxx(4,17ß-xxxxxxxxxxxxxxxx-4-xx-3-xx) |
&xxxx;• |
xxxxxxxxx |
|
|
• |
5-xxxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
7ɑ-xxxxxxx-XXXX |
&xxxx;• |
xxxxxxxxxx (17β-xxxxxxx-2α,17α-xxxxxxx-5α-xxxxxxxxx-3-xx) |
|
|
• |
7ß-xxxxxxx-XXXX |
&xxxx;• |
xxxxx-1-xxxxxxxxxxx (17ß-hydroxy-17ɑ-metyl-5ɑ-androst-1-en-3-on) |
|
|
• |
7-keto-DHEA |
• |
metylklostebol |
|
|
• |
11ß-metyl-19-nortestosteron |
• |
metyldienolon (17β-xxxxxxx-17α-xxxxxxxxxx-4,9-xxxx-3-xx) |
|
|
• |
17ɑ-xxxxxxxxxxxxxxxxxxx (xxxxxxx) |
&xxxx;• |
xxxxxxxxxxxxxxxxxxx (17ß-xxxxxxx-17ɑ-xxxxxxxxx-4-xx-3-xx) |
|
|
• |
19-xxxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxxxxxxxxx |
|
|
• |
19-xxxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxxx (xxxxxxxxxxxxxx, 17ß-xxxxxxx-17ɑ-xxxxxxxxxxx-4,9,11-xxxxx-3-xx) |
|
|
• |
Xxxxxxx-4-xx-3,11,17-xxxxx(11-xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxx) |
&xxxx;• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxxxxx (5ɑ-xxxxxxxxxxxxxxxxxx, 17ß-hydroxy-5ɑ-androstan-3-on) |
• |
nandrolon (19-xxxxxxxxxxxxxx) |
|
|
• |
xxxxxxxxxxxxxx (xxxxxxx-5-xx-3ß,17ß-xxxx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxxxxxxx (xxxxxxx-4-xx-3,17-xxxx) |
&xxxx;• |
xxxxxxxxxxxx (4-xxxxxx-17β-xx-xxxx-4-xx-3-xx) |
|
|
• |
xxxxxxxxxx |
&xxxx;• |
xxxxxxxxxxxxx |
|
|
• |
xxxxxxxx |
&xxxx;• |
xxxxxxxx |
|
|
• |
xxxxxxx (androsta-1,4-dien-3,17-dion) |
• |
oxandrolon |
|
|
• |
calusteron |
• |
oxymesteron |
|
|
• |
klostebol |
• |
oxymetolon |
|
|
• |
danazol ([1,2]oxazolo[4’,5’:2,3]pregna-4-en- 20-xx-17ɑ-xx) |
&xxxx;• |
xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, DHEA, 3β-xxxxxxxxxxxxxx-5-xx-17-xx) |
|
|
• |
xxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx- 17ß-xxxxxxx-17ɑ-xxxxxxxxxxxxx-1,4-xxxx-3-xx) |
&xxxx;• |
xxxxxxxxxxx (17β-[(xxxxxxxxxxxxxxx-2-xx)xxx]-1’X-xxxxxxxx[3,4:2,3]-5α-xxxxxxxxx) |
|
|
• |
xxxxxxxxxxxxxxxxxxxxxx (17ɑ-xxxxxx-5ɑ-xxxxxxx-2-xx-17ß-xx a 17ɑ-xxxxx-5ɑ- xxxxxxx-3-xx-17ß- xx) |
&xxxx;• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxxxxx (7ɑ,11ß-xxxxxxx-19-xxxxxxxxxxxxxx) |
&xxxx;• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
&xxxx;• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxxxxxx (3β-hydroxy-5α-androstan-17-on) |
• |
testosteron |
|
|
• |
epi-dihydrotestosteron (17β-xxxxxxx-5β-xxxxxxxxx-3-xx) |
&xxxx;• |
xxxxxxxxxxxxxxxxxxx (17-xxxxxxx-18x-xxxx-19-xxx-17ɑ-xxxxxx-4,9,11-xxxxx-3-xx) |
|
|
• |
xxxxxxxxxxxxxx |
&xxxx;• |
xxxxxxx |
|
|
• |
xxxxxxxxxxxx (19-norpregna-4-en-17α-ol) |
• |
trenbolon (17β-xxxxxxxxxxx-4,9,11-xxxxx-3-xx) |
|
|
• |
xxxxxxxxxxxxxx |
&xxxx;• |
xxxxxxxxx (7ɑ-xxxxx-19-xxxxxxxxxxxxxx, MENT) |
a xxxxx xxxxx x podobnou xxxxxxxxx strukturou xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.
X1.2. XXXXXXX XXXXXXXXXX XXXXX
Xxxx xxxx včetně:
Clenbuterol, xxxxxxxxxxxx, xxxxxxxxxx, selektivní xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx [XXXX, xxxx. xxxxxxx, xxxxxxxxx (xxxxxxx), XXX-4033 (ligandrol), XXX140, X-23 a XX-11], xxxxxxx a xxxxxxxxxx.
X2 XXXXXXXXX HORMONY, XXXXXXX XXXXXXX, XXXXXXXX XXXXX X XXXXXXXX
XXXXXXXX XXXXX (XXX XXXXXXX X XXXX SOUTĚŽ)
Všechny xxxxxxxx látky x xxxx xxxxx xxxx Xxxxxxxxxxxx látky.
Následující látky x další xxxxx x xxxxxxxx chemickou xxxxxxxxxx nebo xxxxxxxxx xxxxxxxxxxxx účinky xxxx xxxxxxxx.
X2.1. XXXXXXXXXXXXX (XXX) X XXXXX XXXXXXXXXXX XXXXXXXXXXX
Xxxx xxxx xxxxxx:
X2.1.1 Xxxxxxxx xxxxxxxxxxxxxxxxx xxxxxxxxx, xxxx. xxxxxxxxxxxx (xXXX); xxxxxxxxxxxxx (XXX); xxxxxxxxxx xxxxxxxx xx XXX, [xxxx. EPO-Fc, xxxxxxxxxxxxxxxxxxxxxx-xxxxxxx xxxx (XXXX)]; XXX- xxxxxxxxx prostředky x xxxxxx xxxxxxxxxx, xxxx. XXXX-530, peginesatid.
S2.1.2 Xxxxxxxxx xxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxxxxx (XXX), xxxx. xxxxxx; xxxxxxxxxxx (XXX1278863); XXX2; xxxxxxxxxx (BAY 85-3934); roxadustat (XX-4592); xxxxxxxxxx (AKB-6548); xxxxx.
X2.1.3 Xxxxxxxxxx XXXX, např. X-11706.
X2.1.4 Xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxxxxxx xxxxxxxxx faktoru xxxx (TGF-β), xxxx. xxxxxxxxxxxx; sotatercept.
S2.1.5 Agonisté xxxxxxxxx xxxxxxxxx xxxxxxxxx, xxxx. asialo XXX; xxxxxxxxxxxxx XXX (XXXX).
X2.2. XXXXXXXXX XXXXXXX X XXXXXX XXXXXXXXXX XXXXXXX
X2.2.1 Xxxxxxx stimulující testosteron x mužů, xxxx xxxx xxxxxx:
• xxxxxxxx xxxxxxxxxxxx (CG),
• xxxxxxxxxxxx xxxxxx (XX),
• xxxxxx xxxxxxxxxx xxxxxxxxxxxx (XxXX, xxxxxxxxxxx) x jeho xxxxxxxxxxx xxxxxxx (xxxx. xxxxxxxxx, xxxxxxxxxx, goserelin, xxxxxxxxx, xxxxxxxxxxx, nafarelin x xxxxxxxxxxx),
&xxxx;• kisspeptin x xxxx xxxxxxxxxxx xxxxxxx.
X2.2.2 Xxxxxxxxxxxxxx x xxxxxx xxxxxxxxxx faktory, xxxx. xxxxxxxxxxxx x xxxxxxxxxxxxx.
X2.2.3 Xxxxxxx hormon (XX), xxxx xxxxxxx x fragmenty, xxxx xxxx xxxxxx:
• xxxxxxx xxxxxxxxx hormonu, xxxx. xxxxxxxxxxxxxxxxx, somapacitan a xxxxxxxxxx,
• fragmenty xxxxxxxxx xxxxxxx, např. AOD-9604 x xXX 176–191.
S2.2.4 Xxxxxxx xxxxxxxxxx xxxxxxx xxxxxx, mimo xxxx xxxxxx:
• hormon xxxxxxxxxx xxxxxxx hormon (XXXX) x jeho xxxxxxx, xxxx. XXX-1293, XXX-1295, xxxxxxxxxx x xxxxxxxxxxx,
• xxxxxxxxxxx xxxxxxxxx xxxxxxx (XXX) x xxxxxx xxxxxxxx [např. xxxxxxxxxx, xxxxxxxxxxxx, xxxxxxxxxx (XX-677), xxxxxxxxxx, xxxxxxxxxxx (xxxxxxx), xxxxxxxxxxx x xxxxxxxxxxx],
• xxxxxxx xxxxxxxxxx XX (XXXX) [např. alexamorelin, xxxxxxxxxx (xxxxxxxxx), XXXX-1, XXXX-2 (pralmorelin), GHRP-3, XXXX-4, XXXX-5 x XXXX-6].
X2.3. XXXXXXX XXXXXXX X XXXXXXXXXX XXXXXXXXX XXXXXXX
Xxxx xxxx xxxxxx:
• xxxxxxxxxxxxx xxxxxxx xxxxxxx (XXX)
• xxxxxxxxxxxx xxxxxxx xxxxxx (XXX)
• růstový xxxxxx 1 podobný xxxxxxxx (IGF-1, mecasermin) x jeho analogy
• xxxxxxxxxx xxxxxxx xxxxxxx (XXX)
• růstový xxxxxx xxxxxxxx x krevních xxxxxxxx (XXXX)
• thymosin-β4 x xxxx xxxxxxxx, xxxx. XX-500
• xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (VEGF)
a xxxxx xxxxxxx xxxxxxx xxxx xxxxxxxxxx xxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxxx/xxxxxxxxx xxxxxxxx xx xxxxxxx, xxxxxxxx nebo xxxxxx, xxxxxxxxxxxxx, využití xxxxxxx, xxxxxxxxxxxxx kapacitu nebo xxxxxxxxxxx xxxx xxxxxxxxx xxxxxx.
X3 XXXX-2 XXXXXXXX
XXXXXXXX XXXXX (XXX SOUTĚŽI X XXXX XXXXXX)
Xxxxxxx xxxxxxxx xxxxx x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.
Xxxxxxx xxxxxxxxxx x neselektivní beta-2 xxxxxxxx xxxxxx xxxxx xxxxxxxxx xxxxxxx xxxx xxxxxxxx.
Xxxx xxxx včetně:
|
• |
arformoterol |
• |
indakaterol |
• |
reproterol |
• |
tretoquinol (xxxxxxxxxxxxx) |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
XXXXXXX
• Inhalační xxxxxxxxxx: xxxxxxxxx 1600 mikrogramů xx 24 xxxxx x xxxxxxxxxx dávkách, xxxxxxxxxxxxxxxx 600 xxxxxxxxxx xxxxx 8 xxxxx xx xxxxxxxxx dávce;
• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx xxxxxx xxxxx 54 xxxxxxxxxx xx 24 xxxxx;
• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 200 xxxxxxxxxx xx 24 xxxxx;
• xxxxxxxxx xxxxxxxxxx: xxxxxxxxx 25 xxxxxxxxxx za 24 xxxxx.
XXXXXXXX
Xxxxxxxxxx xxxxxxxxxxx x xxxx v xxxxxxxx xxxxxx xxx 1000 xx/xx xxxx xxxxxxxxxxx x xxxxxxxx xxxxxx xxx 40 xx/xx neodpovídá xxxxxxxxxxxxxx xxxxxxx látky x xxxx xxxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx xxxxx (XXX), pokud Sportovec xxxxxxxxx xxxxxxxxxxxxx xxxxxxxxxxxxxxxxx xxxxxx, xx xxxxxxxxxx xxxxxxxx xxx xxxxxxxxx xxxxxxxxxxxx xxxxx (inhalační) xx xx xxxx xxxxxxx xxxxxxxxx xxxxx.
X4 XXXXXXXXX X XXXXXXXXXXX XXXXXXXXXX
XXXXXXXX XXXXX (XXX XXXXXXX X MIMO XXXXXX)
Xxxxxxxx xxxxx ve xxxxxxx X4.1 a X4.2 xxxx Xxxxxxxxxx xxxxx.
Xxxxx zařazené xx xxxx X4.3 x X4.4 jsou Nespecifické xxxxx.
Xxxxxxxxxxx hormonové x xxxxxxxxxxx xxxxxxxxxx jsou xxxxxxxx.
X4.1. INHIBITORY XXXXXXXX
Xxxx xxxx xxxxxx:
|
• |
2-xxxxxxxxxxx (5ɑ-xxxxxxx-2-xx-17-xx) |
• |
xxxxxxxx-1,4,6-xxxxx-3,17-xxxx (xxxxxxxxxxxxxxxxx) |
|
|
• |
2-xxxxxxxxxxx (5ɑ-androst-2-en-17-on) |
• |
androsta-3,5-dien-7,17-dion (arimistan) |
|
|
• |
3-androstenol (5ɑ-xxxxxxx-3-xx-17-xx) |
• |
xxxxxxxxx |
|
|
• |
3-xxxxxxxxxxx (5ɑ-xxxxxxx-3-xx-17-xx) |
• |
xxxxxxxxx |
|
|
• |
4-xxxxxxxxx-3,6,17 xxxxx (6-xxx) |
• |
xxxxxxxx |
|
|
• |
xxxxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
|
|
• |
xxxxxxxxxx |
X4.2. XXXXXXXXXXXXXX XXXXX [XXXXXXXXXXXXX X XXXXXXXXXX XXXXXXXXXX ESTROGENOVÝCH XXXXXXXXX (XXXXX)]
Xxxx xxxx xxxxxx:
|
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx (xxxxxxxxxxxxx) |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
X4.3. XXXXX ZABRAŇUJÍCÍ XXXXXXXX RECEPTORU XXXXXXXX XXX
Xxxx xxxx xxxxxx:
|
• |
xxxxxxxxxx xxxxxxxxxxxxxx aktivin X |
• |
xxxxxxxxxx xxxxxxxxxx, xxxx.: |
|
|
• |
xxxxxxxxxx xxxxxxxxx xxxxxxxx XXX, xxxx.: |
- xxxxx xxxxxxxxx xxxx xxxxxx xxxxxxx xxxxxxxxxx |
||
|
- xxxxxxx receptory xxxxxxxx (xxxx. XXX-031) |
- xxxxxxxx xxxxxx xxxxxxxxx (např. xxxxxxxxxxx, propeptid xxxxxxxxxx) |
|||
|
• |
xxxxxxxxxx xxxxx xxxxxxxxx aktivinu XXX (xxxx. xxxxxxxxxx) |
- xxxxxxxxxx neutralizující myostatin xxxx xxxxxxxxxx (xxxx. xxxxxxxxxxx, xxxxxxx xxxxx, xxxxxxxxxxxxx, xxxxxxxxxx) |
X4.4. XXXXXXXXXXX XXXXXXXXXX
X4.4.1 xxxxxxxxxx XXX-xxxxxxxxxx xxxxxxxxxxxxx (XXXX), xxxx. XXXXX, agonisté peroxizomovými xxxxxxxxxxx xxxxxxxxxxxx receptoru xxxxx (XXXXδ), xxxx. 2-(2-xxxxx-4-((4-xxxxx-2-(4- (xxxxxxxxxxxxx)xxxxx)xxxxxxx-5-xx)xxxxxxxxx)xxxxxx) xxxxxxxx xxxxxx (GW1516, XX501516) x xxxxxxxx Rev-erbɑ , xxxx. SR9009, XX9011
X4.4.2 xxxxxxxx x xxxxxxxx insulinů
S4.4.3 xxxxxxxxx
X4.4.4 xxxxxxxxxxxx
X5 XXXXXXXXX X XXXXXXXXX XXXXX
XXXXXXXX XXXXX (XXX XXXXXXX I XXXX SOUTĚŽ)
Všechny xxxxxxxx xxxxx x xxxx xxxxx jsou Xxxxxxxxxx xxxxx.
Xxxxxxx xxxxxxxxx x xxxxxxxxx látky, včetně xxxxx optických xxxxxxx, xxxx. x- x x-, xxxx xxxxxxxx.
Xxxx xxxx xxxxxx:
•&xxxx; Diuretika, xxxx xxxx.:
xxxxxxxxxxxx; xxxxxxxx; xxxxxxxxx; xxxxxxxx; xxxxxxxxxxxx; xxxxxxxx xxxxxxxxxx; xxxxxxxxx; xxxxxxxxx; metolazon; xxxxxxxxxxxxx; xxxxxxxx, xxxx. xxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxx a xxxxxxxxxxxxxxxxxx; xxxxxxxxx; xxxxxxxxxx;
• Vaptany, xxxx. konivaptan, xxxxxxxxxx, xxxxxxxxx;
• Plazmatické expandéry xxxxxxxx xxxxxxxxxxxx, např.:
albumin, xxxxxxx, hydroxyetyl xxxxx, xxxxxxxx;
• Xxxxxxxxxxx;
• Xxxxxxxxxx;
x xxxxx xxxxx x xxxxxxxx xxxxxxxxx strukturou xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.
XXXXXXX
• xxxxxxxxxxx; xxxxxxxx; x xxxxxxx xxxxxxxxxxxxxx xxxxxxxx xxxxxxxxxx xxxxxxxxxxxxxx (xxxx. xxxxxxxxxx, xxxxxxxxxxx);
• xxxxxxx xxxxxx xxxxxxxxxxx x xxxxx xxxxxxxxx.
XXXXXXXX
Xxxxx xxxxxxxxxxx xxxxxxxx xxxxx xx xxxxxxxxxx prahovým xxxxxxx: x xxxxxxxxxxx, xxxxxxxxxxx, katinu, efedrinu, xxxxxxxxxxxxx x xxxxxxxxxxxxxx xx Xxxxxx Xxxxxxxxx xxxxxxxx nebo xxxxxxxx Xxx Xxxxxxx xx xxxxxxx s xxxxxxxxxx xxxx jinou maskovací xxxxxx (xxxxx xxxxxxxxx xxxxxx podání xxxxxxxxxx xxxxxxxxxxxxxx nebo lokálního xxxxxx xxxxxxxxxxx x xxxxxxxx anestezii), xxxx xxxxxxxxx xx Xxxxxxxxx xxxxxxxxxxx xxxxx (XXX), xxxxx Xxxxxxxxx xxxx xxxxxxxxxx Terapeutickou xxxxxxx (XX) xx xxxx xxxxx xxxxx x xx, xxxxx již xxxx udělena xx xxxxxxxxxx nebo xxxxx xxxxxxxxx látku.
ZAKÁZANÉ METODY
ZAKÁZANÉ XXXXX (PŘI SOUTĚŽI X XXXX SOUTĚŽ)
Všechny xxxxxxxx xxxxxx x xxxx třídě xxxx Xxxxxxxxxxxx s výjimkou xxxxx x M2.2, xxx xxxx Xxxxxxxxxx xxxxxx.
X1. XXXXXXXXXX X XXXX X XXXXXXXX XXXXXXXXXXXX
Xxxxxxxx xx následující:
M1.1. Xxxxxx xxxx opětovné xxxxxxxx jakéhokoliv xxxxxxxx xxxxxxxxx, allogenní (homologní) xxxx xxxxxxxxxxx krve xxxx xxxxxxxx x xxxxxxxxx xxxxxxx xxxxxxxxxxx xxxxxx do xxxxxxxxx xxxxxxx x výjimkou xxxxxxxx xxxxxx xxxx xxxxxx xxxxxx Sportovci xxxxxxxxxxxxxxx xxxxxxxxxxxx provedené x xxxxxxxxxxxxx odběrovém xxxxxx.
X1.2. Xxxxx xxxxxxxxx xxxxxx, přenosu xxxx xxxxxxx xxxxxxx.
Xxxx xxxx xxxxxx:
Xxxxxxxxxxxxxxxxxxx; xxxxxxxxxxx (XXX13); xxxxxxxxx x xxxxxxxxxxxx xxxxxxxxxxxxx produkty, xxxx. xxxxxx xxxxxxxx xx xxxx xxxxxxxxxxx a xxxxxxxxxxxxxxxx hemoglobinové xxxxxxxx, x xxxxxxxx doplňkového xxxxxxx xxxxxxxx.
X1.3. Xxxxxxxxx xxxxx intravaskulární xxxxxxxxxx x xxxx xxxx x krevními komponentami xxxxxxxxxxx xxxx xxxxxxxxxx xxxxxxx.
X2. XXXXXXXX X XXXXXXXXX XXXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
X2.1. Podvádění nebo Xxxxx x podvod xx xxxxxx porušit xxxxxxxxx x xxxxxxxx Xxxxxx xxxxxxxxxx xxx Xxxxxxxxx xxxxxxxx.
Xxxx xxxx xxxxxx:
Xxxxxx a/nebo xxxxxx Xxxxxx, xxxx. přidáním xxxxxxx ke Vzorku.
M2.2. Xxxxxxxxxx infuze x/xxxx xxxxxxx xxxx než xxxxxx 100 ml xx 12 xxxxx xxxxx xxxxxx xxxxxxxxx xxxxxxxxx v xxxxxxx xxxxxxxxxxxx xxxxxxxx, xxxxxxxxxxxxx xxxxxxx xxxx klinických xxxxxxxxxxxxxx xxxxxxxxx.
X3. GENOVÝ X BUNĚČNÝ DOPING
Z xxxxxx xxxxxxxxxxxxxxx zvýšení xxxxxxxxxxx xxxxxx je xxxxxxxx následující:
M3.1. Xxxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxx xxxxxxx, xxxxx xxxxx xxxxxx xxxxxxxx xxxxxx x/xxxx exprese xxxx xxxxxxxxxx xxxxxxxxxxx. Xx mimo jiné xxxxxxxx xxxxxxxxxxx úprav xxxx, xxxxxxxxx xxxx x technologie xxxxxxx xxxx.
X3.2. Xxxxxxx xxxxxxxxxx xxxx xxxxxxxxx modifikovaných xxxxx.
X6 STIMULANCIA
ZAKÁZANÉ XXX XXXXXXX
Xxxxxxx xxxxxxxx látky x xxxx třídě xxxx Specifické xxxxx x výjimkou xxxxx xxxxxxxxx v X6.X, xxx xxxx Nespecifické xxxxx.
Xxxxxxxx xxxxx x xxxx xxxxx: xxxxxx x xxxxxxxxxxxxxxxxxxxxxxxx (MDMA/„extáze“)
Všechna xxxxxxxxxxx, xxxxxx všech xxxxxxxxx xxxxxxx, xxxx. x- x l-, xxxx xxxxxxxx.
Xxxxxxxxxxx xxxxxxxx:
X6.X: XXXXXXXXXXXX XXXXXXXXXXX
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxx [4-xxxxxxxxxxxxxx (xxxxxxxx)] |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxx |
|
|
• |
xxxxxxxxxxxxxxx |
• |
xxxxxxxxxxxx(x-) |
|
|
• |
xxxxxxxxx |
• |
x-xxxxxxxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxx |
• |
xxxxxxxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxxxxxx |
|
|
• |
xxxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxxxx |
• |
xxxxxxxxxx |
|
|
• |
xxxxxxxxx |
• |
xxxxxxxxx |
|
|
• |
xxxxxxxxxxx |
|||
|
• |
xxxxxxxxxxx |
Xxxxxxxxx, xxxxx xxxx xxxxxxxx uveden v xxxxx oddíle, xx Xxxxxxxxxxx xxxxxx.
X6.X: XXXXXXXXXX XXXXXXXXXXX
Xxxx jiné včetně:
|
• |
2-fenylpropan-1-amin (ß-xxxxxxxxxxxxxx-xxxx, XXXXX) |
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
||
|
• |
3-xxxxxxxxxx-2-xxxx (1,2-dimetylpentylamin) |
• |
fenbutrazát |
• |
oxilofrin (xxxxxxxxxxxxx) |
||
|
• |
4-xxxxxxxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxx |
||
|
• |
4-xxxxxxxxxx-2-xxxx (1,3-xxxxxxxxxxxxxxx, 1,3 XXXX, metylhexanamin) |
• |
heptaminol |
• |
pentetrazol |
||
|
• |
4-methylpentan-2-amin (1,3-xxxxxxxxxxxxxxxxx) |
• |
xxxxxxxxxx (xxxxxxxxx) |
• |
xxxxxxxxxxx x jeho xxxxxxxx |
||
|
• |
5-xxxxxxxxxx-2-xxxx (1,4-xxxxxxxxxxxxxxx, 1,4-xxxxxxxxxxxxxxxxx, 1,4-XXXX) |
• |
xxxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxxxxx) |
• |
xxxxxxxxxxx |
||
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxxxx |
||
|
• |
xxxxx1) |
• |
xxxxxxxxxxxxxxx |
• |
xxxxxxxxxxxxxx |
||
|
• |
xxxxxxx x xxxx xxxxxxx, xxxx. xxxxxxxx, xxxxxxxx x ɑ-xxxxxxxxxxxxxxxxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxxxx2) |
||
|
• |
xxxxxxxxxxxxxx (xxxxxxxxxxxxxxxx) |
• |
xxxxxxxxxxxxxxxxxxxxxxxx |
• |
xxxxxxxxx |
||
|
• |
xxxxxxx3) |
• |
xxxxxxxxxxxx3) |
• |
xxxxxxxxxx |
||
|
• |
xxxxxxxxx (xxxxxxxxx)4) |
• |
xxxxxxxxxxxxx [(±)-xxxxx-2-(xxxxxxxx-2-xx)-2-(xxxxxxxxx-2- yl)acetát] |
• |
solriamfetol |
||
|
• |
etamivan |
• |
metylfenidát |
• |
strychnin |
||
|
• |
etylfenidát |
• |
niketamid |
• |
tenamfetamin (xxxxxxxxxxxxxxxxxxxxx) |
||
|
• |
xxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxxxxxx |
||
|
• |
xxxxxxxxx |
• |
xxxxxxxx (1,5-xxxxxxxxxxxxxxxx) |
x další xxxxx x podobnou xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx účinky
VÝJIMKY
• xxxxxxxx;
• xxxxxxxx xxxxxxxxxxx v xxxxxxx xxxxxx xxxxxxx, xxxxxxx, očního xxxx xxxxxx xxxxxxx (např. xxxxxxxxxx, klonazolin, xxxxxxxxxxx, xxxxxxxxxxx, nafazolin, xxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxx) x xxxxxxxxxxx xxxxxxxx xx Monitorovacího xxxxxxxx 20245).
X7 NARKOTIKA
ZAKÁZANÉ XXX XXXXXXX
Xxxxxxx xxxxxxxx xxxxx x této třídě xxxx Xxxxxxxxxx látky.
Návykové xxxxx x xxxx xxxxx: xxxxxxxxx (heroin)
Následující xxxxxxxxx, xxxxxx xxxxxx xxxxxxxxxx xxxxx xxxxxxxxx xxxxxxx, např. x- x l, xxxx xxxxxxxx.
|
• |
xxxxxxxxxxx |
• |
xxxxxxxx x xxxx xxxxxxxx |
• |
xxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxx |
|||
|
• |
xxxxxxxxx (xxxxxx) |
• |
xxxxxxx |
• |
xxxxxxxx |
• |
xxxxxxxx |
|||
|
• |
xxxxxxxxx |
X8 KANABINOIDY
ZAKÁZANÉ XXX XXXXXXX
Xxxxxxx xxxxxxxx xxxxx x této xxxxx xxxx Xxxxxxxxxx xxxxx. Návykové xxxxx x xxxx xxxxx: xxxxxxxxxxxxxxxxxxx (XXX)
Xxxxxxx xxxxxxxx x xxxxxxxxxx xxxxxxxxxxx xxxx zakázané, xxxx.
• x xxxxxx (xxxxx, xxxxxxxxx) x xxxxxxxxx xxxxxxxxxx
• xxxxxxxx x xxxxxxxxxx tetrahydrokanabionoly (XXX)
• xxxxxxxxxx xxxxxxxxxxx xxxxxxxxxxxx xxxxxx XXX
XXXXXXX
• xxxxxxxxxx
X9 XXXXXXXXXXXXXXX
XXXXXXXX PŘI SOUTĚŽI
Všechny xxxxxxxx látky x xxxx xxxxx jsou Xxxxxxxxxx látky.
Všechny glukokortikoidy xxxx xxxxxxxx, pokud xxxx xxxxxxxx xxxxxxxxxx xxxxxxxx, xxxxxxxxx [xxxxxx xxxxxxxxxx (xxxx. xxxxxxx, xxxxxxxxxx, xxxxxxxxxxxx)] nebo xxxxxxxx xxxxxx.
Xxxx jiné xxxxxx:
|
• |
xxxxxxxxxxxx |
• |
xxxxxxxxxxx |
• |
xxxxxxxxx |
||
|
• |
xxxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxxx |
||
|
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxxx acetonid |
||
|
• |
kortizon |
• |
hydrokortizon |
||||
|
• |
deflazakort |
• |
metylprednisolon |
POZNÁMKA
• Xxxx xxxxxxx podání (xxxxxx xxxxxxxxxxx x xxxxxxxxx: xxxxxxxx-xxxxxxxxxxxxxx, dermálního, xxxxxxxxxxxxxx, xxxxxxxxxxxxxxxx, ušního x xxxxxxxxxxxx) nejsou zakázány, xxxxx xx xxxxxxxxx x rámci xxxxxxxx xxxxxxxxxxxx dávek x xxxxxxxxxxxxxx xxxxxxxx.
X1 XXXX-XXXXXXXXX
XXXXXXXX X XXXXXXXX XXXXXXXX
Xxxxxxx xxxxxxxx látky x xxxx xxxxx xxxx Xxxxxxxxxx xxxxx.
Xxxx-xxxxxxxxx xxxx xxxxxxxx pouze x xxxxxxxxxxxxx xxxxxxxx Při Xxxxxxx a xxx xx to xxxxxxxx xxxxxxxx (*) x Xxxx xxxxxx.
• xxxxxxxxxxx (XX)*
• xxxxxxxx/xxxxxxxxxxxx (XXX) – skoky na xxxxxx, akrobatické xxxxx / X-xxxxx x xxxxxxxxx U-rampa / xxx xxx
• xxxxxxxxxxxx xxxxx (XXX)
• xxxxxxxx xxxxxx (XXXX)* v xxxxxxxxxxxx xxxxxxx xxxxxxxx, xxxx harpunou x xxxxxxx xx terč
• xxxxxxxx (xxxxxxx xxxxxxxxxx) (XXXX)
• xxxxx (XXX)
• xxxx (IGF)
• xxxxxxxx (XXX)
• xxxxxxx (ISSF, XXX)*
* xxxxxxxx xxxx Xxxx xxxxxx
Xxxx xxxx xxxxxx:
|
• |
xxxxxxxxxx |
• |
xxxxxxx |
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxxxx |
• |
xxxxxxxxxxxx |
• |
xxxxxxxx |
|||
|
• |
xxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxxxxxx |
|||
|
• |
xxxxxxxxx |
• |
xxxxxxxxxx |
• |
xxxxxxx |
• |
xxxxxxx |
|||
|
• |
xxxxxxxxxx |
• |
xxxxxxx |
• |
xxxxxxxxx |
• |
xxxxxxx |
Xxxxxxx x. 2
Xxxxx xxxxxxxxxxx xxxxxxx x xxxxxxxxx jazyce
1) xxxxx (x-xxxxxxxxxxxxxxxx) x xxxx x-xxxxxx: xx zakázaný xxxxx xxx xxxxxxxxxxx x moči xxxxx xxx 5 mikrogramů x 1 xx.
2) xxxxxxxxxxxxx: zakázaný xxxxx xxx xxxxxxxxxxx v xxxx xxxxx xxx 150 mikrogramů v 1 xx.
3) xxxxxxx x xxxxxxxxxxxx: zakázány xxx xxxxxxxxxxx x xxxx xxxxx xxx 10 mikrogramů v 1 ml.
4) epinefrin (xxxxxxxxx): xxxx xxxxxxxx xxxxxxx xxxxxxxx, např. xxxxx, xxxx, xxxx xxxxxxxx podávání x xxxxxxxxx anestetiky.
5) xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, kofein, xxxxxxx, xxxxxxxxx x xxxxxxxx: xxxx látky xxxx xxxxxxxx xx Xxxxxxxxxxxxxx programu 2024 x xxxxxx xxxxxxxxxx xx Zakázané xxxxx.
Xxxxxxxxx
Xxxxxx předpis x. 19/2025 Sb. xxxxx xxxxxxxxx xxxx 28.1.2024.
Xxxxx xxxxxxxxxxxx právních xxxxx xxxxxx xxxxxxxx xxxxxxxx x xxxxxxxx není xxxxxxxxxxxxx, xxxxx xx xxxx xxxxxx derogační xxxxx xxxxx xxxxxxxxx xxxxxxxx předpisu